[Combining antidepressants: a useful strategy for therapy resistant depression?]

Area of Science:

• Pharmacology
• Neuroscience
• Psychiatry

Context:

• Refractory depression presents a significant clinical challenge, prompting the exploration of advanced treatment modalities.
• Antidepressant combination therapy is a widely adopted strategy for managing treatment-resistant depression.
• This review synthesizes existing literature on antidepressant combinations from 1990-2006.

Purpose:

• To review the benefits and risks associated with various antidepressant combination strategies.
• To inform clinical practice regarding the effective use of combined antidepressant treatments.
• To highlight the need for further research into the comparative efficacy of these combinations.

Summary:

• Antidepressant combinations, particularly those engaging distinct mechanisms (e.g., SSRIs with Reboxetine, Bupropion, Mirtazapine, or Tricyclics; Tricyclics with MAO-Inhibitors), are common in treating refractory depression.
• While effective, these combinations pose safety risks, including pharmacokinetic and pharmacodynamic interactions.
• Potential adverse events include serotonin syndrome with MAOIs and elevated tricyclic levels with certain SSRIs like Fluoxetine, increasing toxicity risk.

Impact:

• Enhanced understanding of antidepressant combination strategies can improve response and remission rates in therapy-resistant depression.
• Clinicians can optimize treatment selection by considering the specific mechanisms and potential interactions of combined antidepressants.
• The findings underscore the urgent need for further research to establish the relative efficacy and safety profiles of different antidepressant combinations.